Your browser is no longer supported. Please, upgrade your browser.
Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.40% Shs Outstand175.72M Perf Week1.60%
Market Cap15.78B Forward P/E- EPS next Y-0.23 Insider Trans-11.51% Shs Float174.97M Perf Month-3.48%
Income-144.40M PEG- EPS next Q-0.26 Inst Own- Short Float6.05% Perf Quarter-4.02%
Sales1.26B P/S12.57 EPS this Y-253.70% Inst Trans-0.03% Short Ratio8.31 Perf Half Y2.92%
Book/sh16.07 P/B5.59 EPS next Y64.60% ROA-3.50% Target Price110.64 Perf Year3.01%
Cash/sh7.15 P/C12.55 EPS next 5Y25.00% ROE-5.20% 52W Range80.10 - 100.51 Perf YTD0.68%
Dividend- P/FCF- EPS past 5Y-51.20% ROI-17.50% 52W High-11.33% Beta1.78
Dividend %- Quick Ratio3.80 Sales past 5Y20.40% Gross Margin81.70% 52W Low11.26% ATR2.26
Employees2293 Current Ratio4.90 Sales Q/Q19.40% Oper. Margin-12.90% RSI (14)50.56 Volatility2.25% 2.21%
OptionableYes Debt/Eq0.41 EPS Q/Q67.90% Profit Margin-11.50% Rel Volume0.74 Prev Close89.78
ShortableYes LT Debt/Eq0.41 EarningsJan 25 AMC Payout- Avg Volume1.27M Price89.12
Recom1.80 SMA20-1.24% SMA503.00% SMA2000.31% Volume938,967 Change-0.74%
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Jan-12-18 08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Jan-11-18 09:03AM  How Akcea Therapeutics Volanesorsen Performed in 3Q17 Market Realist
07:34AM  How Ioniss Spinraza Performed in 3Q17 Market Realist
Jan-10-18 05:40PM  A Look at Ioniss 3Q17 Revenue Stream Market Realist
10:33AM  Analysts Recommendations for Incyte in January 2018 Market Realist
Jan-09-18 11:55AM  How Was Incytes Revenue Stream in 3Q17? Market Realist
08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Jan-08-18 04:45PM  BioMarin's chief calls hemophilia treatment results 'extremely encouraging' CNBC
03:00PM  Full interview with Shire CEO Flemming Ørnskov CNBC Videos
02:00PM  BioMarin CEO on hemophilia treatment success CNBC Videos
01:19PM  How To Trade The JPMorgan Healthcare Conference Benzinga
Jan-06-18 10:30AM  Why This Gene Therapy Pioneer Crashed 29.8% in December Motley Fool
Jan-05-18 09:00AM  Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN) Zacks
Jan-03-18 08:30AM  BioMarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Jan-02-18 02:45PM  Piper Jaffray analyst: What to expect from biotech in 201... CNBC Videos
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Dec-27-17 07:04AM  Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo Zacks
Dec-26-17 09:17AM  BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA Zacks
Dec-22-17 08:30AM  BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018 PR Newswire
Dec-20-17 09:48AM  BioMarin's (BMRN) Gene Therapy Enters First Phase III Study Zacks
Dec-19-17 04:05PM  BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A PR Newswire
03:11PM  New Gene Therapies Could Change Hemophilia Forever Motley Fool
Dec-14-17 07:09PM  ASH 2017 Recap: These Were the Big Winners and Losers Motley Fool
03:26PM  Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform Benzinga
Dec-13-17 02:24PM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : December 13, 2017 Capital Cube
12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
Dec-12-17 03:30PM  3 Reasons Spark Therapeutics Is a Buy After Its Crash Motley Fool
12:31PM  Spark Therapeutics: This Looks Bad Barrons.com
10:32AM  Analysts Recommendations for BioMarin in December 2017 Market Realist
10:15AM  Spark Therapeutics Stock Plunges on Hemophilia Therapy Data Zacks
09:03AM  How Did BioMarin Pharmaceuticals Drugs Perform in 3Q17? Market Realist
08:52AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5% Zacks
08:08AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:34AM  How BioMarin Performed in 3Q17 Market Realist
07:24AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : December 12, 2017 Capital Cube
Dec-11-17 06:04PM  Why Biotech Stocks Are Just Too Darn Scary! Spark Tumbles 35% Barrons.com +7.46%
05:08PM  What Happened in the Stock Market Today Motley Fool
04:24PM  11 Biotech Stocks Moving From ASH 2017 Benzinga
03:30PM  Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting MarketWatch
01:45PM  Spark Therapeutics' gene therapy program brings stock dow... CNBC Videos
12:43PM  Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today Motley Fool
12:09PM  Why BioMarin Pharmaceutical Inc. Stock Is Surging Today InvestorPlace
11:27AM  Biotech winners and losers: ASH Hematology Conference CNBC Videos
10:00AM  BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting PR Newswire
09:39AM  Spark Therapeutics shares slide more than 40% after hemophilia data disappoint MarketWatch
09:02AM  Analyst Recommendations for Alexion in December 2017 Market Realist
08:51AM  Five Winners -- And One Loser -- From Medicine's Big Meeting About Blood Forbes
08:20AM  4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018 Zacks
07:46AM  Spark Shadows BioMarin In Hemophilia Gene Therapy Race Forbes
Dec-09-17 03:02PM  Excitement Builds Around Gene Therapy Cures For Hemophilia Forbes
07:30AM  BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication PR Newswire
Dec-08-17 12:25PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : December 8, 2017 Capital Cube
08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Dec-07-17 04:28PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
09:31AM  These 5 companies could disappear in 2018s wave of M&A MarketWatch
08:05AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Dec-06-17 08:30AM  BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition PR Newswire
Dec-05-17 09:46AM  Here's Why Sarepta Stock is Up More Than 70% in 6 Months Zacks
08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Dec-04-17 08:05AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Dec-01-17 08:05AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Nov-27-17 12:23PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 27, 2017 Capital Cube
08:45AM  BioMarin Sells Second Priority Review Voucher for $125 Million PR Newswire
Nov-24-17 08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Nov-23-17 08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Nov-20-17 08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Nov-17-17 05:16PM  Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease Zacks
08:20AM  Investor Expectations to Drive Momentum within Meritor, Bloomin' Brands, LaSalle Hotel Properties, Northern Trust, Quanta Services, and BioMarin Pharmaceutical Discovering Underlying Factors of Influence GlobeNewswire
Nov-15-17 08:01AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Nov-13-17 11:53AM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 13, 2017 Capital Cube
Nov-08-17 05:44PM  Edited Transcript of BMRN earnings conference call or presentation 26-Oct-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-06-17 04:31PM  9 Notable Biotechs Presenting At This Year's ASH Meeting Benzinga
Nov-03-17 12:00PM  ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 3, 2017 Capital Cube
10:00AM  BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-02-17 07:30AM  Corporate News Blog - Verastem Announces Plans to Submit NDA Requesting Full Approval of Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL ACCESSWIRE
Nov-01-17 04:44PM  BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:40AM  Corporate News Blog - Aviragen Enters Into Merger Agreement with Vaxart ACCESSWIRE
Oct-31-17 08:30AM  BioMarin to Attend Three Upcoming Investor Conferences PR Newswire
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Oct-30-17 08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Oct-27-17 05:50PM  Analyst Recommendations for Vertex Pharmaceuticals in October Market Realist
11:30AM  BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised Zacks
09:03AM  Analysts Recommendations for Biogen in October 2017 Market Realist
Oct-26-17 05:35PM  BioMarin reports 3Q loss Associated Press
04:05PM  BioMarin Announces Third Quarter 2017 Financial Results PR Newswire
11:31AM  Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised Zacks
08:30AM  FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A PR Newswire
08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Oct-25-17 08:00AM  Adgero Biopharmaceuticals Appoints John Liatos as Chief Financial Officer Marketwired
Oct-24-17 08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Oct-23-17 08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
05:41AM  What's in Store for BioMarin (BMRN) This Earnings Season? Zacks
Oct-20-17 08:06AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Oct-19-17 09:00AM  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi Zacks
08:16AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : October 19, 2017 Capital Cube
06:39AM  BioMarin Pharmaceutical: Cramer's Top Takeaways TheStreet.com
Oct-18-17 07:00PM  BioMarin is 'close as can get' to a hemophilia cure, CEO ... CNBC Videos -5.26%
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerJan 05Option Exercise38.5910,000385,900235,894Jan 09 08:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 05Sale90.3210,000903,203225,894Jan 09 08:36 PM
FUCHS HENRY JPresident, Worldwide R&DJan 02Option Exercise33.8015,000507,050148,976Jan 04 07:26 PM
LAWLIS V BRYANDirectorJan 02Option Exercise38.593,750144,71318,610Jan 04 08:16 PM
LAWLIS V BRYANDirectorJan 02Sale88.843,750333,15014,860Jan 04 08:16 PM
FUCHS HENRY JPresident, Worldwide R&DJan 02Sale89.2315,0001,338,401133,976Jan 04 07:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Option Exercise38.5910,000385,900235,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale89.6110,000896,125225,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Option Exercise38.5910,000385,900235,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale89.8910,000898,912225,894Jan 02 05:29 PM
HERON ELAINE JDirectorDec 14Sale88.9080071,11638,385Dec 18 08:56 PM
Davis George EricEVP, General CounselNov 30Sale85.641,200102,76782,942Dec 04 08:26 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.062,915268,35528,761Oct 02 09:07 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.5015,5001,433,676129,083Oct 02 09:07 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Option Exercise37.463,521131,89750,110Sep 26 07:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Sale95.003,521334,49547,944Sep 26 07:19 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Option Exercise33.8015,000507,050151,422Sep 19 03:17 PM
LAWLIS V BRYANDirectorSep 15Option Exercise38.593,750144,71319,660Sep 19 03:27 PM
LAWLIS V BRYANDirectorSep 15Sale91.263,750342,22515,910Sep 19 03:27 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Sale90.5015,0001,357,500136,422Sep 19 03:17 PM
Davis George EricEVP, General CounselJun 23Option Exercise38.599,844379,88093,425Jun 27 08:46 PM
Davis George EricEVP, General CounselJun 23Sale96.609,844950,93083,581Jun 27 08:46 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise21.512,67157,45315,556Jun 23 05:39 PM
Mueller BrianSVP, Corporate ControllerJun 22Sale100.002,671267,10012,885Jun 23 05:39 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Option Exercise37.4660322,588137,025Jun 20 06:33 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Sale90.0060354,270136,422Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Option Exercise38.593,750144,71319,660Jun 20 06:31 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Option Exercise33.6514,397484,462150,819Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Sale90.003,750337,50015,910Jun 20 06:31 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Sale90.0014,3971,295,730136,422Jun 20 06:33 PM
Davis George EricEVP, General CounselJun 09Option Exercise23.549,239217,53083,581Jun 13 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 07Sale89.611,00489,96847,944Jun 09 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Option Exercise17.335,00086,650231,924Jun 06 08:34 PM
Davis George EricEVP, General CounselJun 05Sale91.049,471862,23074,342Jun 07 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Sale90.565,000452,800226,924Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Option Exercise17.335,00086,650238,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Sale89.705,000448,500233,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Option Exercise17.335,00086,650238,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Sale87.535,000437,650233,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Option Exercise17.337,423128,641240,987Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Sale88.297,423655,377233,564Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Option Exercise17.335,00086,650238,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Sale88.385,000441,900233,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise17.335,00086,650238,564May 19 10:33 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Sale91.735,000458,650233,564May 19 10:33 AM
Davis George EricEVP, General CounselMay 16Option Exercise14.391,14616,49185,301May 17 06:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Option Exercise17.335,00086,650243,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Sale89.235,000446,150238,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise17.335,00086,650243,496May 09 01:19 PM
Mueller BrianSVP, Corporate ControllerMay 08Option Exercise21.512,60055,92616,068May 10 03:23 PM
Mueller BrianSVP, Corporate ControllerMay 08Sale91.877,482687,33413,468May 10 03:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale93.175,000465,850238,496May 09 01:19 PM
Davis George EricEVP, General CounselMay 05Option Exercise38.592,50096,47587,751May 09 01:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise17.335,00086,650243,496May 09 01:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Option Exercise36.314,486162,87955,030May 09 01:23 PM
MEIER RICHARD ADirectorMay 05Option Exercise17.337,500129,97534,260May 09 01:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Sale99.004,486444,11451,532May 09 01:23 PM
Davis George EricEVP, General CounselMay 05Sale100.342,500250,85385,251May 09 01:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale99.005,000495,000238,496May 09 01:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 02Sale96.7430229,21551,532May 04 08:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise17.335,00086,650243,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale95.725,000478,600238,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 25Option Exercise17.335,00086,650243,194Apr 27 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 25Sale94.005,000470,000238,194Apr 27 06:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 04Option Exercise14.393,00043,170238,194Apr 06 05:28 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale89.153,890346,79451,532Mar 31 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise71.335,000356,650195,674Mar 17 06:27 PM
Davis George EricEVP, General CounselMar 16Sale91.962,238205,80673,729Mar 17 06:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 16Sale91.961,989182,90814,471Mar 17 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale91.965,000459,800190,674Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise17.335,00086,650211,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale91.425,000457,100206,364Mar 17 06:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise17.335,00086,650211,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale92.685,000463,400206,364Mar 15 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Option Exercise17.335,00086,650211,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale91.095,000455,450206,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise17.336,000103,980212,364Mar 13 07:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale90.186,000541,080206,364Mar 13 07:59 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 07Sale90.565,000452,80046,510Mar 08 07:31 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 06Sale93.322,303214,91620,761Mar 08 07:28 PM
Davis George EricEVP, General CounselMar 06Sale93.321,498139,79378,962Mar 08 07:24 PM
LAWLIS V BRYANDirectorMar 01Option Exercise17.337,500129,97521,360Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 01Sale94.505,000472,50025,347Mar 02 06:20 PM
LAWLIS V BRYANDirectorMar 01Sale95.007,500712,50013,860Mar 02 06:14 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Option Exercise63.1030,0001,893,00060,347Mar 02 06:20 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerFeb 28Sale94.0030,0002,820,00030,347Mar 02 06:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 26Sale84.005,000420,000170,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Option Exercise17.335,00086,650175,682Jan 27 05:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 25Sale84.445,000422,200170,682Jan 27 05:46 PM